【摘要】 目的 回顾性总结经肝动脉化疗栓塞治疗晚期肝癌临床疗效及技术经验。方法 对12例肝癌采用经肝动脉灌注化疗栓塞治疗，观察临床疗效。部分超选择血管困难的患者采用微导管技术选到准确的靶血管。结果 全部12例半年生存率92%，1年生存率67%，2年生存率17%。巨块型或单发结节型生存平均15个月，多发结节或弥漫型平均生存8个月，差异有显著性(P<0.01)。微导管技术应用9次，出现梗阻3次。结论 经肝动脉灌注化疗栓塞治疗肝癌疗效确实，对中晚期肝癌尤为重要。其中巨块型或单发结节型的治疗效果好于多发结节或弥漫型的。应用微导管技术要解决灌注碘油导管梗阻和反流问题。

    【关键词】 肝癌；介入放射学；化疗栓塞；微导管技术

    The clinical therapeutic efficacy and technique experience of transhepatic arterial chemoembolization in patients with end stage hepatocellular carcinoma

    ZHANG Chen-wu,CHEN Hong-mei,REN Rui-jun,et al.

    The First Hospital,Huhehaote City,Internal Mongolia 010020,China

    【Abstract】 Objective Summarize the clinical efficacy and technique experience retrospectively of transacatheter hepatic arterial chemoembolization(TACE) on patients with end stage hepatocellular carcinoma.Methods 12 patients with liver cancer used TACE then observed clinical efficacy .Some part of patients whose hepatic artery was difficult to reach used microcatheter to choose accurate target blood vessels.Results Among 12 patients half-year survival is 92%, one-year survival is 67%, and 17% patients up to 2 years. The patients with large mass or single nodule tumor survived 15 months on average , for others with multi-nodules or diffusible tumor was 8 months on average. It showed significant difference (P<0.01). Micro-catheter technique was practiced 9 times, and obstruction appeared 3 times.Conclusion The efficacy of TACE is stable ,especially to patients with end stage liver cancer. And the therapy result of large mass or single nodule hepatocarcinoma is better than multi-nodules or diffuse tumor. ......